12:00 AM
Jan 17, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

5G1.1: Phase Ib study update

Alexion Pharmaceuticals Inc. (ALXN), New Haven, Conn.
Product: 5G1.1
Business: Renal
Therapeutic category: Membrane attack...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >